Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
& Prabhakar, P
Why stopping and starting can be risky For many patients, stopping is not really a choice
Location: Indianapolis, IndianaWarning Letter Date: September 9, 2025FDA Department Issuing Warning: Center for Drug Evaluation and Research (CDER)Type of Warning: False & Misleading Claims/Misbranded DrugsSubject of Violation: An Oprah Special: Shame, Blame, and the Weight Loss Revolution, regarding Zepbound (tirzepatide) and Mounjaro (tirzepatide)FDA Warning: In the program, which aired on television in 2024 and until recently was available continuously on the ABC website and through various streaming services, Eli Lilly promoted Mounjaro and Zepbound in a manner that failed to present the serious risks of these drug products in a truthful and nonmisleading manner, despite FDAs prior correspondence (advisory comments dated June 13, 2022 and June 21, 2022)
Reduced metabolic stress: Lower weight, improved insulin sensitivity, and better glucose control reduce the metabolic burden on organs that are damaged by diabetes
However, we found another nine clinical trials that are ongoing: six for alcohol, one for opiates and two for nicotine (Supplementary Section 3)
nejm.org/doi/full/10.10 After trying multiple weight loss plans with little success, I was shocked to see how medications like tirzepatide could drive such dramatic resultsbut I also realized it's not just about the drug
US$ 28.54
US$ 21.24
US$ 28.42
US$ 19.99
US$ 22.69
US$ 26.43
US$ 20.15
US$ 25.22
US$ 23.94
US$ 28.98
US$ 25.67
